Kano Therapeutics

About Kano Therapeutics

Kano Therapeutics is a biotech company focused on targeted correction of gene-length stretches of DNA using a new class of biomaterial: circular single-stranded DNA. Their mission is to develop safe and effective genetic payloads to achieve genetic cures.

Products & Services

Circular Single-Stranded DNA (ssDNA):A biomaterial for genomic engineering that combines the stability of double-stranded DNA and the flexibility of RNA, offering precise insertion, safer genome editing with lower immune activation, and structural flexibility for functional 2D/3D features.

Fermentation-Based ssDNA Production:A cost-effective manufacturing method for producing gene-length circular single-stranded DNA templates at scale.

ssDNA Sequence Design Databank:A first-of-its-kind databank linking ssDNA sequence design to activity, aimed at speeding up development timelines and reducing costs for partners.

Specialties

Genomic Engineering Single-Stranded DNA (ssDNA) Production Therapeutic Gene Editing DNA Donor Material Optimization

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 5000000 MR: - FA: $5 million FAN: 5000000	D: 2024-08-12 FD: 2024-08-12	4 investors

Seed Latest

2024-08-12

$5.0M

4 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

F

Floris Engelhardt

CEO/CSO & Co-Founder

J

John Vroom

Chief Business Officer & Co-Founder

S

Scott Hamilton

Director, CMC

C

Christian Burns

Lead, Platform Engineering and Analytics

K

Kimberly Wong

Lead, Preclinical Biology

B

Beaven Ankner-Edelstein

Senior Research Associate

View 12 more team members with Pro

Unlock Full Team Directory

Recent News